Top of this page
Skip navigation, go straight to the content
Posted by Eimear O'Brien, Brand Communications 13-Feb-2012
Posted by Antje Witte, Investor Relations 23-Jan-2012
Where did the Christmas holidays go? Somehow it’s almost February already but at least January brought a major piece of good news: we won an award!
Posted by France Nivelle, Global Communications & Change Support 06-Dec-2011
Here at UCB, we listen. We listen to patients, we listen to health care professionals, we listen to investors and we listen to our colleagues.
Posted by Eimear O'Brien, CNS Communications 09-Nov-2011
Posted by Antje Witte, Investor Relations 27-Oct-2011
Posted by Nathalie Vandenbruaene, Global Digital Operations 27-Oct-2011
Here at UCB we’re always trying to improve our website. And, thanks to you, we’re moving in the right direction.
Posted by Lesley McMenamin, Business Unit CNS, UCB Australia 07-Oct-2011
Six-time World Champion cyclist, Marion Clignet, is living proof of what can be achieved by people living with epilepsy.
Posted by Antje Witte, Investor Relations 13-Sep-2011
Posted by Eimear O'Brien, CNS Communications 08-Sep-2011
The Excellence in Epilepsy Journalism Award has created a virtuous cycle by encouraging top health journalists to deepen public understanding of epilepsy.
Posted by Eimear O'Brien, CNS Communications 01-Sep-2011
Calling all health and medical journalists who have written or broadcast about epilepsy!
Posted by Antje Witte, Investor Relations 29-Jul-2011
Posted by Henrik Klitgaard, CNS Research 07-Jul-2011
Here at UCB, we are always delighted to see excellent researchers recognised for their valuable work.
Posted by Eimear O'Brien, CNS Communications 19-May-2011
UCB and the International Bureau for Epilepsy (IBE) are pleased to launch the 2011 Excellence in Epilepsy Journalism Award.
Posted by Antje Witte, Investor Relations 29-Apr-2011
Annual Report shows UCB’s biopharma aspirations on trackThe 2010 Annual Report is now available on the UCB website. Offering more than just financial results, this year’s report highlights and analyses UCB’s 2010 activities as it advanced its goals of becoming the patient-centric biopharmaceutical leader.